Abstract
The recent debâcle concerning allegations of intentionally withholding damaging longitudinal outcomes data by investigators supported with funds from the manufacturer of Celebrex [1–3] once again raises the issue of a temptation to compromise ethics in research. Researchers and authors supported by pharmaceutical manufacturers are in an unenviable position due to pressures from their ‘dual relationship’, wherein they are simultaneously functioning in two conflicting roles – to serve as doctoral level scientists, and to recognize and report findings satisfactory to the parent drug maker on whom the scientist may be dependent for current and future remuneration. Medical journals generating revenue from drug advertisements and the journal editors themselves also experience this dependent, symbiotic, dual relationship. ‘The journals are the major force for quality control in scientific work’ [4] and, coincidentally, the journals become the easiest point in the system to implement fail-safe mechanisms rapidly, in order to increase further the integrity of the manuscript’s findings. The following are equitably and respectfully proposed:
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
